Neurolief
Neurolief delivers FDA‑cleared wearable neuromodulation therapies for migraine and depression.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $60M
AI Company Overview
Neurolief delivers FDA‑cleared wearable neuromodulation therapies for migraine and depression.
NeurologyPsychiatry
Technology Platform
Wearable non‑invasive electro‑cutaneous nerve stimulation (e‑COTNS) targeting occipital and trigeminal nerves to modulate cortical excitability and pain pathways.
Opportunities
Global expansion of Relivion into Europe and Asia, and commercial launch of Proliv™Rx for depression could unlock multi‑billion‑dollar markets.
Risk Factors
Regulatory clearance timelines, reimbursement uncertainty, and competition from other neuromodulation devices could impede growth.
Competitive Landscape
Key competitors include Cefaly, Nerivio, and gammaCore; Neurolief differentiates by simultaneous occipital‑trigeminal stimulation and a fully digital therapeutic platform.